Nevertheless, the development of an antitumor drug that targets an upstream driver of the AKT/mTOR pathway (e.g., BYSL or RIOK2) will reduce the drug toxicity caused by targeting a combination of different molecules in the pathway, and may possibly achieve precise treatment for glioma patients with EGFR amplification and/or PTEN deficiency. This evidence concerns the gene EGFR and central nervous system cancer.